MedTrace Logo

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

NCT01450579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2017-09-29

No results posted yet for this study

Summary

This trial is to investigate the clinically recommended dosage for ASP7373 based on the comparison of the immunogenicity and safety among the three doses of ASP7373 in healthy adults.

Conditions

  • Healthy

Interventions

BIOLOGICAL

ASP7373

Intermuscular administration

BIOLOGICAL

Placebo

Intramuscular administration

Sponsors & Collaborators

  • UMN Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450579 on ClinicalTrials.gov